FSD Pharma Inc. (HUGE) News
Filter HUGE News Items
HUGE News Results
|Loading, please wait...|
HUGE News Highlights
- HUGE's 30 day story count now stands at 5.
- Over the past 19 days, the trend for HUGE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- MS are the most mentioned tickers in articles about HUGE.
Latest HUGE News From Around the Web
Below are the latest news stories about FSD Pharma Inc that investors may wish to consider to help them evaluate HUGE as an investment opportunity.
Toronto, Ontario--(Newsfile Corp. - May 12, 2021) - On Monday, May 10, 2021, at the request of Messrs. Anthony Durkacz and Zeeshan Saeed, founding shareholders and members of the group of concerned shareholders (the "Concerned Shareholders") of FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FSE: 0K9A) (the "Company" or "FSD"), the Ontario Superior Court of Justice (Commercial List) (the "Court") issued an order appointing Ms. Carol Hansell as independent chair of the Company's shareholders' ...
FSD Pharma Announces That ISS Recommends Shareholders Vote for the Company’s Nominees to the Board Using Only the BLUE Proxy
FSD Pharma Inc. (the "Company") today announced that Institutional Shareholder Services Inc. ("ISS"), a leading independent international corporate governance analysis and proxy advisory firm, has recommended that shareholders vote FOR all Company Director Nominees (the "Management Director Nominees") in a contested election for the Board of Directors and FOR the elimination of the dual-class share structure (the "Dual-Class Sunset") at the annual and special meeting of shareholders on May 14, 2021 (the "Meeting").
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the "Company" or "FSD Pharma") is pleased to announce the appointment of Nathan Coyle, the Company's Corporate Controller as its Interim Chief Financial Officer, following the departure of Donal Carroll, effective immediately.
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the "Company" or "FSD Pharma") wishes to alert you to the events that have occurred since the Company filed its Management Information Circular (the "Circular") and the accompanying letter to shareholders related to the Annual & Special Meeting of shareholders scheduled for May 14, 2021, copies of which are available under the Company's SEDAR profile. On April 26, 2021, certain dissident shareholders issued an information circular which included misleading statements and baseless accusations towards the Company's management. In response, the Company issued the following letter to shareholders:
FSD Pharma Inc. (Nasdaq:HUGE) (CSE:HUGE) (the "Company" or "FSD Pharma") announces the filing of its Management Information Circular (the "Circular") and an accompanying letter to shareholders related to the Annual & Special Meeting scheduled for May 14, 2021, copies of which are available under the Company's SEDAR profile.
HUGE stock is screaming for the top after the company announced a licensing agreement. This could be a short squeeze.
Gainers FSD Pharma Inc. (NASDAQ: HUGE) shares rose 50.7% to $3.12 in pre-market trading as the company entered into a license agreement to develop FDA …
HUGE stock is on the move Wednesday after FSD Pharma announced a potentially lucrative move in the pet care market. Here's what to know.
bluebird bio, Inc. (NASDAQ: BLUE ), Onconova Therapeutics, Inc. (NASDAQ: ONTX ), FSD Pharma Inc. (NASDAQ: HUGE ) and Immatics N.V. (NASDAQ: IMTX ) are among the biggest biopharma movers in Wednesday's session. Executive Exodus At Bluebird Bio: Bluebird Bio has seen a couple of high-profile departures recently amid a setback in its gene therapy program for sickle cell disease. The company revealed in a filing that Chief Medical Officer David Davidson has left as of Tuesday. Davidson, however, will continue as a consultant for a period of six months to provide guidance and support for the biopharma's late-stage programs in severe genetic disease, the company said. Earlier this week, Joanne Smith-Farrell, who served as COO and business unit head for oncology at bluebird bio, jumped ship to...
FSD Pharma announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…